Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

D. Provencher · SciRah

Researcher profile · Semantic Scholar

D. Provencher

Share profile

D. Provencher — researcher profile on SciRah

h-index: 57
Works: 278
Citations: 14K

Most-cited papers

Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial
S. D. de Boer, M. Powell, L. Mileshkin, D. Katsaros +68 more
2018The Lancet Oncology560 citations Open access
Semantic Scholar
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial
S. D. de Boer, M. Powell, L. Mileshkin, D. Katsaros +68 more
2019The Lancet Oncology395 citations Open access
Semantic Scholar
A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)
Bradley J. Monk, C. Parkinson, M. Lim, D. O'Malley +35 more
2022Journal of Clinical Oncology346 citations Open access
Semantic Scholar
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.
A. Oza, A. Tinker, A. Oaknin, R. Shapira-Frommer +21 more
2017Gynecologic Oncology258 citations Open access
Semantic Scholar
Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes
Yi-Kan Wang, A. Bashashati, M. Anglesio, D. Cochrane +32 more
2017Nature Genetics256 citations
Semantic Scholar
Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence
Hubert Fleury, N. Malaquin, Véronique Tu, Sophie Gilbert +9 more
2019Nature Communications205 citations Open access
Semantic Scholar
Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)
E. Swisher, T. Kwan, A. Oza, A. Tinker +30 more
2021Nature Communications179 citations Open access
Semantic Scholar
The molecular origin and taxonomy of mucinous ovarian carcinoma
D. Cheasley, Matthew J. Wakefield, G. Ryland, Prue E. Allan +60 more
2019Nature Communications167 citations Open access
Semantic Scholar
Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial
J. D. del Campo, U. Matulonis, S. Malander, D. Provencher +17 more
2019Journal of Clinical Oncology165 citations Open access
Semantic Scholar
Uterine Serous Carcinoma
G. Bogani, I. Ray-Coquard, N. Concin, N. Ngoi +28 more
2021Gynecologic Oncology136 citations Open access
Semantic Scholar
Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial
M. Friedlander, V. Gebski, E. Gibbs, L. Davies +18 more
2018The Lancet Oncology122 citations Open access
Semantic Scholar
Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II
Maaike H. M. Oonk, B. Slomovitz, P. Baldwin, H. V. van Doorn +55 more
2021Journal of Clinical Oncology115 citations Open access
Semantic Scholar
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
L. Gilbert, A. Oaknin, U. Matulonis, G. Mantia-Smaldone +8 more
2023Gynecologic Oncology113 citations Open access
Semantic Scholar
A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer
A. Oza, M. Estevez-Diz, E. Grischke, M. Hall +14 more
2020Clinical Cancer Research104 citations
Semantic Scholar
Genomic analysis of low‐grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities
D. Cheasley, Abhimanyu Nigam, Magnus Zethoven, Sally M. Hunter +17 more
2020Journal of Pathology102 citations Open access
Semantic Scholar
Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial.
A. Oza, U. Matulonis, S. Malander, S. Hudgens +16 more
2018The Lancet Oncology99 citations
Semantic Scholar
Dose-Ranging and Cohort-Expansion Study of Monalizumab (IPH2201) in Patients with Advanced Gynecologic Malignancies: A Trial of the Canadian Cancer Trials Group (CCTG): IND221
A. Tinker, H. Hirte, D. Provencher, M. Butler +8 more
2019Clinical Cancer Research78 citations Open access
Semantic Scholar
Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers
C. Le Page, K. Rahimi, M. Köbel, P. Tonin +17 more
2018BMC Cancer78 citations Open access
Semantic Scholar
Green versus blue: Randomized controlled trial comparing indocyanine green with methylene blue for sentinel lymph node detection in endometrial cancer.
A. Rozenholc, V. Samouëlian, T. Warkus, P. Gauthier +5 more
2019Gynecologic Oncology75 citations
Semantic Scholar
A randomized phase 2 trial of epigenetic priming with guadecitabine and carboplatin in platinum-resistant, recurrent ovarian cancer
A. Oza, U. Matulonis, Angeles Alvarez Secord, J. Nemunaitis +24 more
2019Clinical Cancer Research61 citations Open access
Semantic Scholar
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: Interim results from the phase 2 KEYNOTE-100 study.
U. Matulonis, R. Shapira-Frommer, A. Santin, A. Lisyanskaya +16 more
201859 citations
Semantic Scholar
OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer
D. Provencher, C. Gallagher, W. Parulekar, J. Ledermann +17 more
2018Annals of Oncology57 citations Open access
Semantic Scholar
EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer.
R. Arend, A. M. Davis, P. Chimiczewski, D. O'Malley +4 more
2019Gynecologic Oncology49 citations
Semantic Scholar
Hormonal and reproductive factors and the risk of ovarian cancer
Anita Koushik, A. Grundy, M. Abrahamowicz, J. Arseneau +8 more
2017Cancer Causes and Control48 citations
Semantic Scholar
Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial.
M. Fabbro, K. Moore, A. Dørum, A. Tinker +16 more
2019Gynecologic Oncology47 citations Open access
Semantic Scholar
Carboplatin response in preclinical models for ovarian cancer: comparison of 2D monolayers, spheroids, ex vivo tumors and in vivo models
M. Brodeur, Kayla Simeone, Kim Leclerc-Deslauniers, Hubert Fleury +3 more
2021Scientific Reports45 citations Open access
Semantic Scholar
Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses
E. Kang, D. Cheasley, Cécile Lepage, M. Wakefield +39 more
2020Modern Pathology42 citations Open access
Semantic Scholar
Functionally Null RAD51D Missense Mutation Associates Strongly with Ovarian Carcinoma.
B. Rivera, Massimo Di Iorio, J. Frankum, J. Nadaf +28 more
2017Cancer Research40 citations
Semantic Scholar
Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma.
Marta Llaurado Fernandez, A. Dawson, Hannah Kim, N. Lam +14 more
2020Gynecologic Oncology39 citations
Semantic Scholar
Shift Work Patterns, Chronotype, and Epithelial Ovarian Cancer Risk
Lisa Leung, A. Grundy, J. Siemiatycki, J. Arseneau +5 more
2019Cancer Epidemiology, Biomarkers and Prevention35 citations
Semantic Scholar
Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer.
E. Swisher, R. Kristeleit, A. Oza, A. Tinker +18 more
2021Gynecologic Oncology33 citations Open access
Semantic Scholar
Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis.
C. Le Page, K. Rahimi, M. Rodrigues, V. Heinzelmann-Schwarz +13 more
2019Gynecologic Oncology28 citations
Semantic Scholar
Molecular characterization of low-grade serous ovarian carcinoma identifies genomic aberrations according to hormone receptor expression
D. Cheasley, M. Fernández, M. Köbel, Hannah Kim +15 more
2022npj Precision Oncology27 citations Open access
Semantic Scholar
A Keratin 7 and E-Cadherin Signature Is Highly Predictive of Tubo-Ovarian High-Grade Serous Carcinoma Prognosis
L. Communal, N. Roy, Maxime Cahuzac, K. Rahimi +3 more
2021International Journal of Molecular Sciences25 citations Open access
Semantic Scholar
Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status Phase II LIGHT study primary analysis
K. Cadoo, Fiona Simpkins, C. Mathews, Ying L. Liu +10 more
2022Gynecologic Oncology23 citations Open access
Semantic Scholar
High-dimensional analysis of the adenosine pathway in high-grade serous ovarian cancer
Y. Bareche, Sandra Pommey, Mayra S. Carneiro, L. Buisseret +10 more
2021Journal for ImmunoTherapy of Cancer23 citations Open access
Semantic Scholar
Low-grade serous carcinoma (LGSC): A Canadian multicenter review of practice patterns and patient outcomes.
S. Scott, Marta Llaurado Fernandez, Hannah Kim, L. Elit +18 more
2020Gynecologic Oncology23 citations
Semantic Scholar
Carboplatin sensitivity in epithelial ovarian cancer cell lines: The impact of model systems
Bishnubrata Patra, M. A. Lateef, M. Brodeur, Hubert Fleury +5 more
2020PLoS ONE22 citations Open access
Semantic Scholar
Inhibition of nicotinamide dinucleotide salvage pathway counters acquired and intrinsic poly(ADP-ribose) polymerase inhibitor resistance in high-grade serous ovarian cancer
Skye Alexandre Sauriol, E. Carmona, Molly L. Udaskin, N. Radulovich +6 more
2023Scientific Reports21 citations Open access
Semantic Scholar
ENGOT-OV44/FIRST study: A randomized, double-blind, adaptive, phase III study of platinum-based therapy with dostarlimab (TSR-042) + niraparib versus standard-of-care (SOC) platinum-based therapy as first-line treatment of stage 3/4 non-mucinous epithelial ovarian cancer (OC).
A. Hardy-Bessard, K. Moore, M. Mirza, B. Asselain +16 more
2019Journal of Clinical Oncology20 citations
Semantic Scholar
A functionally impaired missense variant identified in French Canadian families implicates FANCI as a candidate ovarian cancer-predisposing gene
Caitlin T. Fierheller, Laure Guitton-Sert, W. M. Alenezi, T. Revil +26 more
2021Genome Medicine15 citations Open access
Semantic Scholar
Modeling the Diversity of Epithelial Ovarian Cancer through Ten Novel Well Characterized Cell Lines Covering Multiple Subtypes of the Disease
Skye Alexandre Sauriol, Kayla Simeone, L. Portelance, Liliane Meunier +8 more
2020Cancers15 citations Open access
Semantic Scholar
A COEUR cohort study of SATB2 expression and its prognostic value in ovarian endometrioid carcinoma
C. Le Page, M. Köbel, Liliane Meunier, D. Provencher +2 more
2019The Journal of Pathology: Clinical Research15 citations Open access
Semantic Scholar
Genetic analyses of DNA repair pathway associated genes implicate new candidate cancer predisposing genes in ancestrally defined ovarian cancer cases
W. M. Alenezi, Caitlin T. Fierheller, C. Serruya, T. Revil +15 more
2023Frontiers in Oncology13 citations Open access
Semantic Scholar
NR1D1 regulation by Ran GTPase via miR4472 identifies an essential vulnerability linked to aneuploidy in ovarian cancer
Zied Boudhraa, Kossay Zaoui, Hubert Fleury, Maxime Cahuzac +6 more
2021Oncogene13 citations Open access
Semantic Scholar
The successful phase 3 niraparib ENGOT-OV16/NOVA trial included a substantial number of patients with platinum resistant ovarian cancer (OC).
J. D. del Campo, M. Mirza, J. Berek, D. Provencher +16 more
201712 citations
Semantic Scholar
Maveropepimut-S, a DPX-Based Immune-Educating Therapy, Shows Promising and Durable Clinical Benefit in Patients with Recurrent Ovarian Cancer, a Phase II Trial
O. Dorigo, A. Oza, T. Pejovic, P. Ghatage +10 more
2023Clinical Cancer Research11 citations Open access
Semantic Scholar
The Genetic and Molecular Analyses of RAD51C and RAD51D Identifies Rare Variants Implicated in Hereditary Ovarian Cancer from a Genetically Unique Population
W. M. Alenezi, L. Milano, Caitlin T. Fierheller, C. Serruya +17 more
2022Cancers11 citations Open access
Semantic Scholar
Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2
G. Konecny, A. Oza, A. Tinker, A. Oaknin +22 more
2021Gynecologic Oncology11 citations Open access
Semantic Scholar
ENGOT-OV44/FIRST study: a randomized, double-blind, adaptive, phase III study of standard of care (SOC) platinum-based therapy ± dostarlimab followed by niraparib ± dostarlimab maintenance as first-line (1L) treatment of stage 3 or 4 ovarian cancer (OC).
A. Hardy-Bessard, K. Moore, M. Mirza, B. Asselain +16 more
202011 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

A. Mes-Masson×21
Invite
A. Mes-Masson — researcher profile on SciRah
A. Oza×10
Invite
A. Oza — researcher profile on SciRah
M. Köbel×9
Invite
M. Köbel — researcher profile on SciRah
D. O'Malley×8
Invite
D. O'Malley — researcher profile on SciRah

×8

Invite

A. Tinker — researcher profile on SciRah

Invite

K. Rahimi — researcher profile on SciRah

Invite

A. Oaknin — researcher profile on SciRah

U. Matulonis×7

Invite

U. Matulonis — researcher profile on SciRah

Invite

K. Moore — researcher profile on SciRah

R. Kristeleit×6

Invite

R. Kristeleit — researcher profile on SciRah

I. Ray-Coquard×6

Invite

I. Ray-Coquard — researcher profile on SciRah

Hubert Fleury×6

Invite

Hubert Fleury — researcher profile on SciRah